The LNP patent landscape features more than 2,500 patents covering a wide spectrum of innovations in this field. It is worth noting that (nearly 40%) drug formulations are poorly soluble in aqueous media, limiting drug delivery efficiency, thereby increasing demand for advanced formulation technologies like lipid nanoparticles (LNPs). Presently, researchers are evaluating approximately 70% of BCS class II drugs across different clinical stages, providing a wide opportunity for the use of LNPs in...

The global AI virtual companions market, valued at USD 34 billion in 2025, is projected to reach USD 44 billion in 2026 and USD 361 billion by 2035, with a CAGR of 26.4% during the forecast period 2026 to 2035. With regards to companion type, the text-based AI companions segment dominates the market by securing nearly 45% of the overall revenue share. In terms of application area, the social interaction and companionship segment holds the largest share of the market. North America region current...

The global biosimilars market, valued at USD 28.0 billion in 2025, is projected to reach USD 32.3 billion in 2026 and USD 130.1 billion by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035. With respect to distribution channel, hospital pharmacies dominate (nearly 45%) the current market. In terms of geographical regions, currently, Europe holds the highest market share (over 50%). The most recent advancement in the biologics and biosimilars market has been the launch of...

The fill finish pharmaceutical contract manufacturing market, valued at USD 7.2 billion in 2024, is project to reach USD 7.5 billion in 2025 and USD 12.1 billion by 2035, representing a CAGR of 4.8% during the forecast period 2025 to 2035. Fill finish of small molecules is final step in the downstream processing of a product, wherein the desired formulation is mixed with the necessary excipients and stabilizers, followed by filling the purified bulk formulation into the pre-sterilized packaging...

The global immune checkpoint inhibitors market, valued at USD 75 billion in 2025, is projected to reach USD 82 billion in 2026 and USD 146 billion by 2035, with a 6.6% CAGR during the forecast period 2026 to 2035. John E. Dick (American Association for Cancer Research Hematologic Malignancies Working Group Committee Member) says that ‘It’s become clear that clonal hematopoiesis is influencing how immune checkpoint inhibitor therapy works in certain subsets of patients. the lung cancer segmen...

The global plasma fractionation market valued at $ 5.3 billion in 2025, is project to reach $ 5.8 billion in 2026 and $ 12.7 billion by 2035, representing a higher CAGR of 9.1% during the forecast period 2026 to 2035. In terms of type of company, the in-house manufacturers’ segment holds the highest share of the market.In terms of scale of operation, the commercial segment dominates the global market. Based on the type of plasma-derived therapeutic products manufactured, immunoglobulins segme...

Diabetes is a chronic disease growing at an alarming rate across the globe. Over 382 million people are estimated to be currently suffering from the disease; the number is likely to increase to 592 million by 2035. With a very high prevalence, especially in some regions such as China and India, an increasing proportion of diabetic patients are likely to benefit from more efficient and accurate diagnostic tests in the future. HbA1c, adapted for clinical testing to monitor diabetes in 1990s, is on...

The human microbiome market, valued at USD 0.63 billion in 2025, is projected to grow to USD 0.85 billion in 2026 and USD 3.27 billion by 2035, representing a CAGR of 16% during the forecast period. It is worth mentioning that, owing to the rising interest, a number of start-ups / small firms have established in the past few years and the contributions of big pharma players have fueled the overall growth in human microbiome market. Driven by increasing prevalence of disease indications, promisin...

The next generation antibody therapeutics market, valued at USD 4.94 billion in 2025, is projected to reach USD 5.45 billion in 2026 and USD 5.76 billion by 2035, with a CAGR of 1% during the forecast period 2026 to 2035. In June 2025, AbTherx entered into a collaboration with GPCR Therapeutics to discover and develop antibodies for novel GPCR targets. In 2025, immunotoxins segment holds most of the market share owing to their superior targeted cytotoxicity and effectiveness against resistant c...

The mRNA synthesis and manufacturing market is estimated to be USD 0.56 billion in 2026. It is expected to reach USD 4.20 billion by 2035, representing a CAGR of 40.9% between 2028 and 2035. In June 2025, Ethris entered into a collaboration with Thermo Fisher Scientific, combining the former company’s comprehensive mRNA technology platforms with Thermo Fisher’s manufacturing capabilities, with an aim to advance mRNA therapeutics from research to clinical stages. In 2025, commercial scale sub...

The global B-cell Inhibitors market, valued at USD 21.2 billion in 2025, is projected to reach USD 24.6 billion in 2026 and USD 51.5 billion by 2035, with a 8.6% CAGR during the forecast period 2026 to 2035. In September 2025, Zenas BioPharma collaborated with Royalty Pharma for up to USD 300 million in funding for the development of Obexelimab for autoimmune disorders. The B-cell Inhibitors therapy pipeline analysis shows that 51% of the B-cell Inhibitors are currently in phase II of developme...

The global RSV vaccine market size, valued at $1,149.41 million in 2025, is anticipated to reduce to $987.83 million in 2026 and $731.05 million by 2040. Respiratory Syncytial Virus (RSV) is a widespread virus that primarily affects the lower respiratory tract, leading to infectious diseases. In September 2024, WHO gave a global recommendation for maternal RSV immunization, with a single dose of RSV vaccine in the third trimester of pregnancy. As per WHO, around 33 million new cases of RSV disea...

The sustainable refrigeration technology market is estimated to grow from USD 69.4 billion in 2026 to reach USD 114.3 billion in 2032 and USD 211.5 billion by 2040, representing a higher CAGR of 8.3% during the forecast period. In 2026, the equipment sub-segment captures the majority (70%) of the overall market and is likely to grow at a higher CAGR of 8.35%.

The global anti-aging drugs market, valued at USD 79 million in 2025, is projected to reach USD 150 million in 2026 and USD 2,807 million by 2040, with a 23.3% CAGR during the forecast period 2026 to 2040. The National Institute of Health around 7.2 million American citizens aged above 65 and above live with diseases, such as Alzheimer. In January 2025, the Dog Aging Project secured a USD 7 million grant to expand its clinical trial of an anti-aging drug. It is worth highlighting that the mar...

The psychedelic drugs market is estimated to grow from USD 2.77 billion in 2024 to reach USD 3.19 billion in 2025 and USD 12.89 billion by 2035, representing a higher CAGR of 15% during the forecast period. In the same month, Cybin secured a $500 million financing deal with High Trail Capital, starting with a $50 million initial tranche to support late-stage psychedelic programs CYB003 and CYB004 for mental health disorders. In the same month, Filament Health announced positive data from phase 2...

The AI in oncology market is estimated to grow from USD 1.7 billion in 2024 to reach USD 2.4 billion in 2025 and USD 9.1 billion by 2035, representing a higher CAGR of 14.1% during the forecast period. Further, more than 35 million new cancer cases are likely to be diagnosed by 2050. According to the International Agency for Cancer Researchers, the number of cancer-associated deaths is likely to increase by 72%, by 2030. In February 2025, Myriad Genetics signed a strategic partnership with PATHO...

The vaccine development companies produced an estimated 7 billion doses of vaccines globally, in the year 2024 and are expected to produce around 8 billion doses in 2025. In January 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) has made a significant new investment of $ 24 million in the Vaccine and Infectious Disease Organization (VIDO), aiming to bolster global preparedness for future infectious disease outbreaks as the world continues to recover from the last pandemic. Nota...

Several market players are focusing on strategic initiatives to strengthen their product portfolio and expand innovation. For instance, in January 2025, Bayer Consume Health (Germany) launched, CanesMeno®, a unique science-backed product range and defined digital education resources crafted by the experts for the first time in the UK. The product is specifically designed to support health of 13 million women in the UK who are experiencing menopausal / premenopausal condition. Similarly, a lot o...

The targeted protein degradation market is estimated to grow from USD 0.48 billion in 2024 to reach USD 1.00 billion in 2025 and USD 6.94 billion by 2035, representing a higher CAGR of 21% during the forecast period. In June 2025, SEED Therapeutics announced the appointment of Dr. Bill Desmarais as the Chief Financial Officer and Chief Business Officer, who previously served as Chief Business Officer at Alchemab Therapeutics. In May 2025, Kesmalea Therapeutics appointed Tim Clackson to its board...

The biostimulants market is estimated to grow from USD 2.88 billion in 2024 to reach USD 3.18 billion in 2025 and USD 8.60 billion by 2035, representing a higher CAGR of 10.45% during the forecast period. The farm bill describes biostimulants as substances or microorganisms that stimulate natural processes to enhance nutrient uptake, nutrient efficiency, tolerance to abiotic stress, or crop quality and yield. In May 2025, TPG and Renaissance Partners jointly acquired a stake in SICIT. An Italy-...